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Significance statement: The paper presents the first musculoskeletal pain prognostic stratification 
tool specifically for use among all primary care patients with the five most common musculoskeletal 
pain presentations (back, neck, knee, shoulder or multisite pain). The Keele STarT MSK tool identifies 
groups of musculoskeletal pain patients with clearly different characteristics and prognosis. Using 





Background: Patients with musculoskeletal pain in different body sites share common prognostic 
factors. Using prognosis to stratify and treatment match can be clinically and cost-effective. We 
aimed to refine and validate the Keele STarT MSK tool for prognostic stratification of 
musculoskeletal pain patients.  
Methods: Tool refinement and validity was tested in a prospective cohort study, and external validity 
examined in a pilot cluster RCT. Study population comprised 2414 adults visiting UK primary care 
with back, neck, knee, shoulder or multisite pain returning postal questionnaires (cohort: 1890 (40% 
response); trial: 524). Cohort baseline questionnaires included a draft tool plus refinement items. 
Trial baseline questionnaires included the Keele STarT MSK tool. Physical health (SF-36 Physical 
Component Score (PCS)) and pain intensity were assessed at 2- and 6-months cohort follow-up; pain 
intensity was measured at 6-months trial follow-up. 
Results: The tool was refined by replacing (3), adding (3) and removing (2) items, resulting in a 10-
item tool. Model fit (R2) was 0.422 and 0.430 and discrimination (c-statistic) 0.839 and 0.822 for 
predicting 6-month cohort PCS and pain (respectively). The tool classified 24.9% of cohort 
participants at low, 41.7% medium and 33.4% high risk, clearly discriminating between subgroups. 
The tool demonstrated model fit of 0.224 and discrimination 0.73 in trial participants. Multiple 
imputation confirmed robustness of findings.  
Conclusions: The Keele STarT MSK tool demonstrates good validity and acceptable predictive 
performance, and clearly identifies groups of musculoskeletal pain patients with different 
characteristics and prognosis. Using prognostic information for stratification and treatment 






Low back and neck pain are among the leading causes of disability globally, with other 
musculoskeletal disorders making substantial contributions (Vos et al., 2012). The impact on 
individuals is considerable, with wider implications such as the heavy burden on healthcare (Jordan 
et al., 2010; March et al., 2014), and lost productivity for society (Woolf and Pfleger, 2003; Yelin et 
al., 2019). Musculoskeletal pain is therefore a research priority (GBD 2015 DALYs and HALE 
Collaborators, 2016; Buchbinder et al., 2018). 
Stratified care involves targeting treatments according to patient subgroups, maximising treatment 
benefit and reducing potential harm or unnecessary interventions (Hingorani et al., 2013). 
Stratification and targeted treatment is particularly appropriate for patients with musculoskeletal 
pain due to the wide individual variability in prognosis, plethora of available treatments and the 
variation in treatment response between patients (Kamper et al., 2015; Linton et al., 2018; Stanton 
et al., 2010; Patel et al., 2013; Foster et al., 2013). One particular approach in low back pain (LBP), 
combining a prognostic stratification tool (STarT Back tool (Hill et al., 2008)) with matched 
treatments, showed significantly better clinical and economic outcomes in the UK (Hill et al., 2011; 
Foster et al., 2014; Whitehurst et al., 2012; Whitehurst et al., 2015), and is now recommended in LBP 
guidelines in the UK (National Institute for Health and Clinical Excellence, 2016) and elsewhere (Van 
Wambeke et al., 2017; New South Wales Agency for Clinical Innovation, 2016; Chenot et al., 2017). 
LBP represents approximately 20% of all primary care musculoskeletal consultations, and the other 
four most common pain presentations are neck, knee, shoulder and multisite pain (Jordan et al., 
2010). Systematic reviews have identified various prognostic factors that predict poor outcome 
across a range of musculoskeletal pain presentations (Mallen et al., 2007; Henschke et al., 2012; 
Artus et al., 2017), and evidence has shown that a single chronic pain risk score can predict 
outcomes across pain conditions (Von Korff and Dunn, 2008; Thomas et al., 2008; Muller et al., 




lower limb or multisite pain showed that a single tool was able to predict outcome across pain sites, 
but required modification as baseline risk varied for the different pain sites (Hill et al., 2016). 
The overall aim of this study was to refine and validate a prognostic stratification tool (the Keele 
STarT MSK tool) for use among all patients consulting in UK primary care with back, neck, knee, 
shoulder or multisite pain. 
 
METHODS 
The Keele Aches and Pains Study (KAPS) was designed to refine and test construct validity of the 
Keele STarT MSK tool (Campbell et al., 2016). External validation of predictive performance was 
conducted within a pilot cluster randomised controlled trial (STarT MSK pilot trial). 
 
Refinement and validation 
Design and participant recruitment 
The KAPS study is a prospective cohort study of patients (18 years and over) consulting a general 
practitioner (GP) for one (or more) of the five most common musculoskeletal pain presentations – 
back, neck, knee, shoulder or multisite pain (Jordan et al., 2010). Participants were recruited 
between July 2014 and February 2015 from 12 general practices in Staffordshire and West Midlands, 
UK. Relevant Read codes (symptom and diagnostic codes used in UK primary care), entered into 
electronic records during visits were used to detect potential participants. Consecutive eligible 
patients were identified through weekly-to-fortnightly electronic record searches. Patients received 
a postal invitation letter, information sheet, consent form and questionnaire, and were given 
prepaid return envelopes. Follow-up questionnaires were sent 2- and 6-months later, with 





Patients were excluded if there were indications of potentially serious underlying pathology (e.g. 
fracture, infection), urgent care needs (e.g. Cauda Equina Syndrome), if patients were vulnerable 
(e.g. diagnosed dementia, persistent severe mental health problems, terminal illness, recent trauma 
or bereavement) and those unable to communicate in English. 
Cohort study questionnaires contained the draft Keele STarT MSK tool (identical to the modified 
STarT Back tool (Hill et al., 2016)). The draft tool comprised items covering pain sites, activity 
restriction, fear avoidance, catastrophising, anxiety, depression, and pain bothersomeness. 
 
Primary outcome measures 
The primary measures for assessing predictive performance were pain intensity (mean of numerical 
ratings scales for least, average, and current pain over the last 2-weeks (Dunn et al., 2010) and self-
reported physical health (SF-36 version 2 physical component summary score (PCS)) (Ware, 2000), 
assessed at 2- and 6-months follow-up. Minimal data included the SF-12v2, which is a shortened 
version of the SF-36 version 2 (Ware et al., 1996).  
 
Potential candidate items for refining the Keele STarT MSK tool 
Eighteen candidate items were identified for potential addition or replacement within the refined 
tool and included in cohort study baseline questionnaires. Candidate items were selected based on 
previous research identifying generic prognostic factors for musculoskeletal pain (Mallen et al., 
2007; Henschke et al., 2012; Artus et al., 2017; Von Korff and Dunn, 2008; Campbell et al., 2013; 
Nicholls et al., 2013), with the predictive value of individual items investigated within existing 
datasets where possible (Campbell et al., 2013; Dunn & Croft 2005; Hill et al., 2008; Hill et al., 2011; 
Foster et al., 2014). Items were assessed for suitability, face validity and readability by the research 




with 10 PPIE members, supported by two PPIE co-ordinators to ensure autonomy. The PPIE group 
comprised people with experience of musculoskeletal pain similar to the target population. Item 
refinements were made, such as wording changes to facilitate simple yes/no response formats. 
Candidate items covered domains including: vitality/fatigue, comorbidity, coping, sleep problems, 
previous treatment success, pain interference, pain self-efficacy, pain persistence, pain-related 
depression, and fear-avoidance. The final choice, wording and format of candidate items was made 
by the research team based on all available information. The candidate items were included in the 
questionnaire in the same format and section as the draft Keele STarT MSK tool items. 
 
Additional measures 
Measures used to describe the population and differences between risk subgroups included pain 
duration (Dunn and Croft, 2006), pain spread, pain interference (Amtmann et al., 2010) and 
bothersomeness (Dunn and Croft, 2005), pain catastrophizing (Harland and Georgieff, 2003), pain 
self-efficacy (Nicholas, 2007), illness perceptions (Nicholls et al., 2013; Moss-Morris et al., 2002), 
sleep problems (Jenkins et al., 1988), social support (Krumholz et al., 1998), health-related quality-
of-life (EQ-5D-5L) (Herdman et al., 2011), health literacy (Morris et al., 2006), comorbidity, and 
employment factors (Campbell et al., (2016) contains further details). The STarT Back tool (Hill et al., 
2008), for those with LBP, and the short-form Örebro Musculoskeletal Pain Screening Questionnaire 
(ÖMSPQ) (Linton et al., 2011) were used to assess cross-sectional construct validity. 
 
External validation of the Keele STarT MSK tool 
The STarT MSK pilot trial is a pilot cluster randomised controlled trial (RCT) with the same inclusion 
and exclusion criteria as the KAPS cohort study (Trial registration: ISRCTN 15366334). Recruitment 




control and four intervention practices). Similar to the cohort, participant identification was based 
on electronic Read codes, but the trial also included GP point-of-consultation eligibility confirmation 
using Read code activated computer templates. Patients were invited using similar methods to the 
cohort study. Baseline questionnaires contained the refined Keele STarT MSK tool. The primary 
outcome was pain intensity (usual pain over the previous 2-weeks on a 0-10 numerical rating scale) 
at 6-months; this question has comparable validity to the composite pain intensity measure used in 
the cohort (Dunn et al., 2010). Control arm patients received usual care for their musculoskeletal 
pain; care for intervention arm patients was informed by the Keele STarT MSK Tool and matched 
treatment options (Protheroe et al., 2019). 
 
Sample size 
The sample size for the cohort study (1,250 patients at 6-months) was calculated based on the 
requirement of ≥100 patients per low, medium and high subgroups, anticipating ≥10% of 
participants in the smallest subgroup (Campbell et al., 2016). Study monitoring indicated lower 
response rates than estimated, therefore the number of patients identified was increased to ensure 
sufficient participants with data at 6-months. The STarT MSK pilot trial sample size was based on 




There were four specific objectives: to (1) refine the Keele STarT MSK tool based on predictive 
performance and validity; (2) determine tool risk-strata cut-points based on optimal predictive 
performance and suitability for matched treatment options; (3) describe tool subgroups and 




paper publication (Campbell et al., 2016); additional protocol paper objectives relating to qualitative 
and health economic analyses are or will be reported elsewhere (Saunders et al., 2016). 
For analyses with dichotomous outcomes, poor outcome on the PCS was defined as scores <37.17 at 
2-months and <39.61 at 6-months, based on lower tertiles from an independent study of UK primary 
care musculoskeletal pain patients (Salisbury et al., 2013). Poor outcome on pain intensity was 
defined as scores ≥5 (Von Korff et al., 1992). To provide clinical cut-offs of good / poor outcomes for 
the two main outcome measures, we pre-defined dichotomies in our protocol paper. The SF-36 PCS 
was dichotomised at 37.17 and 39.61 at 2- and 6-month follow-up (respectively), based on lower 
tertiles extracted from a similar cohort (Salisbury et al., 2013), and pain intensity divided at a score 
of 5 (a score of 5 or more denotes moderate/ severe pain (Von Korff et al., 1992)). 
1. Refining the tool 
An iterative process was used in tool refinement, considering improvements achieved (predictive, 
face and construct validity) compared with the draft tool when replacing existing items or adding 
items, one-by-one. This was carried out during testing (in the cohort study) as initially planned, plus 
following examination of the refined tool in the trial dataset (when items that were not treatment 
modifiable were considered). 
Predictive performance was determined using linear regression of the association between baseline 
tool score and PCS and pain intensity at 2- and 6-month cohort follow-up. Performance was assessed 
based on model fit (R2) and discrimination (C-statistic, with 95% confidence intervals (CI)) and 
calibration (calibration slope and Hosmer–Lemeshow test). 
Item redundancy and weighting was investigated within multiple linear regression models for 
estimating PCS and pain intensity at 2- and 6-month cohort follow-up (i.e. 4 models). If items did not 
add significant predictive performance and/or if average standardized beta weight was small (i.e. 




considered in research team decisions about removal of statistically redundant items. Variable 
weights were applied to reflect the strength of independent associations across non-redundant 
items (integer weights used to retain scoring simplicity). 
2. Determining tool cut-points 
The cut-point for identifying the high risk subgroup (versus medium / low risk) was based on 
classification on the full score most likely to attain positive predictive values and specificity ≥0.8, and 
positive likelihood ratio ≥5, for predicting PCS and pain intensity at 2- and 6-month cohort follow-up. 
The cut-point for categorising the low risk subgroup (versus medium / high risk) was based on the 
classification most likely to achieve negative predictive values and sensitivity ≥0.80, and negative 
likelihood ratio ≤0.2 (Hayden and Brown, 1999, Grimes and Schulz, 2005, Jaeschke et al., 1994). All 
decisions about tool cut-points were based on statistical information in the sample overall and 
within pain sites, plus suitability for matched treatments. 
3. Describing the tool subgroups 
Proportions classified into low, medium and high risk subgroups were described overall and by pain 
site. Means (with standard deviation; SD), medians (interquartile range; IQR) or frequencies and 
percentages (as appropriate) of outcomes were reported at cohort baseline, 2- and 6-months for 
each risk subgroup. Construct (discriminant) validity was assessed by testing differences between 
risk subgroups on baseline characteristics using ANOVA for linear tests and chi-square test-for-trend 
for categorical outcomes. Variations were examined across pain sites. 
Tool cross-sectional construct validity was assessed by calculating agreement (percentage 
agreement and Cohen's kappa, 95% CI) of Keele STarT MSK tool stratification (low risk vs. combined 
medium and high risk subgroups) versus the two ÖMSPQ risk categories at baseline (using the cut-




MSK tool stratification into low, medium, and high risk subgroups versus STarT Back tool subgroups 
was calculated (Cohen’s weighted kappa). 
4. External validation 
External validation of the Keele STarT MSK tool was examined in STarT MSK pilot trial data. 
Discriminant and predictive validity was investigated using model fit and discrimination as above. 
Descriptive analysis of outcomes within risk strata of the final Keele STarT MSK tool were 
investigated. 
Missing data 
Percentages of missing data for each variable were determined and patterns of missingness 
explored. Sensitivity analysis using multiple imputation (40 imputations) was conducted using tool 
items plus a range of baseline and follow-up variables encompassing the domains measured, via 
chained equations with predictive mean matching function for numerical variables and logit/ologit 
functions for categorical variables.  
Ethical Approval 
Ethical approval for the KAPS study was granted by South East Scotland Research Ethics Committee 
(14/SS/0083). Approval for the STarT MSK pilot trial was granted by NHS Health Research Authority 
(16/EM/0257). All participants gave informed consent to provide data. 
 
RESULTS 
Refinement and validation sample 
4720 patients visited their GP about back, neck, knee, shoulder or multisite pain and were invited to 




participate (40.2% adjusted response due to incomplete / ineligible questionnaires / refusals). The 
mean age of participants was 58.3 years (range 18 to 96 years), and 60.6% were female. 
Over half of the cohort stated that the pain they visited their GP about (their index pain) was at 
multiple sites (51.5%). LBP was the next most common (21.6%), followed by knee (18.5%), shoulder 
(5.4%) and neck pain (3.0%). The mean baseline PCS score was 36.2 (SD 10.1), mean pain intensity 
was 5.3 (SD 2.4) and 21.7% of the sample reported having had their pain for less than 3-months. 
Further cohort characteristics are reported in Table 1. 
Response at 2- and 6-months was 75.8% (n=1425) and 78.7% (n=1452) respectively. At 2-months 
and 6-months, mean PCS scores rose to 38.1 and 38.6 respectively (indicating improved physical 
health); 47.7% (n=560) and 53.4% (n=581) were categorised as having a poor outcome. Mean pain 
intensity at 2-months fell to 4.4, and 4.1 at 6-months with 45.6% (n=582) and 42.3% (n=482) 
categorised with a poor pain outcome. Mean pain interference score reduced to 60.1 and 59.1 
respectively. In total, 17.8% indicated they were completely recovered or much improved at 2-
months and 24.3% at 6 months. 
External validation sample 
1237 consultations were identified as back, neck, knee, shoulder or multisite pain in the trial. 524 
patients (both study arms) returned baseline questionnaires with consent (42.3% response); their 
mean age was 61.1 years and 60.7% were female. The most common index pain site (coded by the 
GP) was LBP 29.6%, followed by knee 27.5%, shoulder 23.7%, neck 11.3% and multisite pain 8.0%. 
From baseline questionnaires, mean pain intensity was 6.2 (SD 2.3); further characteristics are 
presented in Table 1. Response at 6-months was 91.4% (n=479) and mean pain intensity dropped to 
4.1 (SD 2.9) with 42.1% (n=201) categorised as having a poor outcome. 




In initial refinement stages, three items were replaced as they improved model fit and 
discrimination, as well as offering better face validity compared to original items. Model fit for PCS at 
2-month follow-up improved to 0.405 and discrimination improved to 0.815, see Table 2. Hosmer-
Lemeshow calibration chi square tests were 6.14 (P=0.631) at 2-months and 3.26 (P=0.917) at 6-
months with calibration slopes of 1.003 and 1.004, respectively. Improvements were similar for pain 
intensity. Table 3 describes original and replacement items, with reasons for change. 
This revised version was then examined within the external validation sample. Model fit dropped to 
0.149 and discrimination fell to 0.69 against pain intensity at 6-months. Due to this drop, and 
because discrimination fell below the cut-off for acceptable discrimination (0.70), the decision was 
made to go back to the refinement and validation sample and investigate changes to further 
improve performance. Three additional items improved tool performance and / or improved face 
validity without detriment to performance, and were therefore added (Table 3). Item redundancy 
was subsequently investigated by examining the magnitude of the standardized beta coefficients 
(averaged across four models for predicting PCS and Pain at 2 and 6 months) and statistical 
significance for the predictors in the multiple linear regression model. On this basis, three tool items 
were considered redundant (items on dressing, anxiety and low mood), i.e. these items had average 
beta coefficients <0.05 and were mostly not statistically significant. In research team discussions, it 
was agreed to remove two items, but it was felt to be important for face validity to include an item 
on low mood given its clinical importance for primary care decision-making. Average beta values for 
all items are shown in Table 3. The beta value for pain intensity was much larger than the other 
items, so a decision was made to weight the scoring in favour of this item (compared to the others). 
There was little difference in performance statistics between a model using actual beta values as 
weights, and a simplified model where weights of 1 were given to all (retained) items except pain 
intensity, therefore a simplified approach was taken which assigned a weight of 3 to pain intensity 




The final Keele STarT MSK tool comprises 10-items with model fit of 0.422 and discrimination 0.839 
for PCS at 6-month cohort follow-up (Table 2). Performance was also perceived to be acceptable 
across the pain sites. Multiple imputation indicated that tool performance was robust to missing 
data: model fit was consistently above 0.4 and discrimination was consistently above 0.8, showing 
similar results as the primary (available case) analysis. 
2. Tool cut-points for defining risk subgroups 
The cut-points determined to provide the best combination of sensitivity, specificity, predictive 
values and likelihood ratios, in combination with suitability for matched treatments, overall and 
across pain sites, were 0-4 for low risk, 5-8 for medium risk, and 9-12 for high risk, on the full scale 
(see table S1). The cut-point of 0-4 / 5+ ensured a consistently high negative predictive value such 
that lower risk patients as classified by the tool (scores 0-4) would have over 80% chance of having 
low pain/ high function (and conversely less than 20% chance of having high pain / low function) and 
medium/higher tool classification (scores 5+) ensures over 80% of truly poor outcome patients are 
captured (sensitivity >0.8); whilst keeping specificity as high as possible. The cut-point of 0-8 / 9+ 
ensured a consistently high positive predictive value such that higher risk patients with scores 
between 9-12 would have over 80% chance of having high pain/ low function (and conversely less 
than 20% chance of having low pain / high function) and low/medium tool classification (scores 0-8) 
ensures over 80% of truly better outcome patients are not given high risk classification (specificity > 
0.8); whilst keeping sensitivity as high as possible. These cut-points also provide consistent good 
performance across individual pain sites (as indicated by summary results in the table S1 footer).   
3. Describing the tool subgroups 
The proportion of cohort participants classified in low, medium and high risk strata based on the 
Keele STarT MSK tool were 24.9%, 41.7% and 33.4%, respectively. Characteristics of participants in 
each risk stratum are shown in Table 4. Overall, discriminant validity is clear: scores consistently 




outcomes reported by participants stratified as medium or low risk. These patterns were still evident 
when the sample was stratified by pain site. 
Cross-sectional construct validity was demonstrated through the ‘moderate’ kappa for agreement 
between stratification by the Keele STarT MSK tool and the ÖMSPQ: 0.49 and 0.48 ‘moderate’ for 
the two possible Keele STarT MSK tool cut-offs, with overall agreement 76% and 73% (see Table 
5[A]). The discordance in the [A] cross-tabulations is due to the Keele STarT MSK tool medium risk, 
which over-classifies low risk and under-classifies high-risk (when classified alongside low risk), and 
under-classifies low risk and over-classifies high risk (when classified alongside high-risk). For 
patients with LBP, the weighted kappa for agreement between stratification by the Keele STarT MSK 
tool and the STarT Back tool was 0.52 ‘moderate’ and 0.64 ‘substantial’ for linear and quadratic 
weights respectively; discordance was greater in respect of higher risk categorisation of the Keele 
STarT MSK tool than the STarT Back tool (i.e. off-diagonal counts being higher on the left-side of the 
cross-tab than the right-side at a ratio of 171:61) (see Table 5[B]). The observed strong correlation of 
0.8 between the numerical scales for Keele STarT MSK tool versus ÖMSPQ and the STarT Back tool 
(see footer of Table 5) further indicates strong construct validity of the Keele STarT MSK tool. 
4. External validation 
In the external validation sample, the Keele STarT MSK tool demonstrated model fit of 0.224 and 
discrimination 0.73 for pain intensity at 6-month follow-up (Table 2). Among all baseline 
participants, 25.3% were classified at low risk, 50.0% medium and 24.7% high risk. When stratified 
by pain site, 12.8% (multisite pain) to 33.5% (neck or shoulder pain; combined due to low numbers) 
of participants were classified at low risk, with 16.5% (neck or shoulder pain) to 33.3% (multisite 
pain) classified at high risk. Mean 6-month pain intensity was 5.7 in the high risk subgroup, 4.1 in 







We have refined and validated the first musculoskeletal pain prognostic stratification tool 
specifically for use among primary care patients with the five most common musculoskeletal pain 
presentations (back, neck, knee, shoulder or multisite pain). The tool clearly and simply allocates 
patients to subgroups with distinct characteristics and different prognosis, and its performance is 
acceptable upon external validation. 
This study has confirmed that generic prognostic factors can be combined to produce a stratification 
tool appropriate for use among patients with a range of musculoskeletal pain presentations. While 
there are no existing tools specifically designed for stratifying all primary care patients with 
musculoskeletal pain, comparison with the ÖMSPQ (developed to predict time to return-to-work 
following work-related soft tissue injuries (Linton et al., 2011, Linton and Boersma, 2003)) indicated 
moderate agreement. The tool also demonstrated substantial agreement with the STarT Back tool 
(Hill et al., 2008) among patients with LBP. Comparison with other instruments such as the Optimal 
Screening for Prediction of Referral and Outcome Yellow Flag Tool (developed in a physical therapy 
setting (Lentz et al., 2016)) or the Graded Chronic Pain Scale-Revised (developed in a general 
population sample (von Korff et al., 2020)) would also be helpful. 
The approach of refinement and validation was robust and comprehensive, utilising information on 
item selection from systematic reviews of generic prognostic factors, a bespoke prospective cohort 
to test key aspects including face validity (using information both from clinicians and service users), 
construct validity (using available prognostic tools), predictive performance (using clinically 
meaningful outcomes), plus examination of external validity. Refining or updating an existing tool (as 
done here) is preferable to developing new ones, as updated versions are then based on both 
original and new data, leading to improved stability and generalisability (Moons et al., 2009). The 
plans for the cohort study and the refinement and validation of the tool were published (Campbell et 




validation of predictive performance, which we felt was essential prior to the tool being 
disseminated and implemented. 
There are also some limitations. In the refinement / validation (cohort) study, just over 40% of those 
invited took part. This could lead to bias if participants were systematically different to non-
participants. This may result in differences in the proportions of patients in the risk subgroups, but is 
less likely to have influenced the refinement of the tool itself, as comparisons are internal within the 
dataset. There were large differences in the proportion with each pain site between the refinement 
/ validation study and the external validation sample, most notably for multisite pain (51.5% cohort, 
8.0% trial). This was predominantly due to the fact that cohort study patients self-reported their pain 
site, whereas participating GPs recorded index pain sites in the trial. That the tool demonstrated 
discrimination and prediction in both scenarios is an indicator of robustness, strengthened by the 
performance of the tool within groups with different pain sites. Performance in the refinement / 
validation cohort and the external sample was generally similar, indicating good generalisability, 
although predictive performance, as expected, was lower in the external sample. This may reflect 
differences in the sample, as although many characteristics of the two samples were similar (e.g. 
pain intensity 6.2 at baseline and 4.1 at follow-up in both), more people were allocated to high risk 
in the refinement / validation sample (33.4%), compared to the external validation sample (24.7%). 
Further external validation in other samples is needed to further examine this. In the external 
sample, the only identical outcome available was pain intensity, so it was not possible to assess 
external performance against physical health, or further examine construct validity. The analysis was 
undertaken using self-report data from postal questionnaires, and further testing with electronic 
versions may be needed. Our aim was to produce a tool for use among all patients consulting with 
back, neck, knee, shoulder or multisite pain, regardless of duration of pain, but further analysis 




We have produced a prognostic stratification tool suitable for use among patients with the five most 
common musculoskeletal pain presentations in UK primary care (available at 
https://www.keele.ac.uk/startmsk/). Over 95% of the UK population are registered with a GP, and in 
light of demonstrated validity and predictive performance, the Keele STarT MSK tool may be broadly 
generalizable to people seeking healthcare for musculoskeletal pain in other settings, although 
further studies are needed to confirm this. The tool identifies distinct groups of patients with 
different prognoses and clearly identifiable characteristics, which can inform treatment decisions. 
For example, patients classified at low risk generally have a good prognosis, and may only need 
advice and support to self-manage. Patients classified at high risk have increased likelihood of a poor 
prognosis, a more complex clinical presentation, often with physical and/or psychosocial 
comorbidities, and may require more intensive healthcare intervention.  
The Keele STarT MSK tool was developed as part of a programme of work investigating stratified 
primary care for patients with musculoskeletal pain. The main STarT MSK trial is ongoing, therefore it 
is inappropriate to speculate on whether using the tool, alongside matched treatment options 
(Protheroe et al., 2019), improves patient outcomes. 
This paper reports the refinement and validation of a brief prognostic stratification tool for use 
among patients with the five most common musculoskeletal pain presentations in primary care: the 
Keele STarT MSK tool. It has demonstrated strong results in terms of validity and acceptable 
performance, and clearly identifies groups of patients with different characteristics and prognosis. 
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Table 1: Baseline characteristics of the KAPS cohort study (internal validation and 
refinement) and STarT MSK pilot trial (external validation) populations  




   
Age, mean (SD) 58.3 (16.1) 61.1 (14.8) 
Female, n (%) 1145 (60.6%) 318 (60.7%) 
Index pain site, n (%)1   
     Knee 349 (18.5%) 144 (27.5%) 
     Neck 57 (3.0%) 59 (11.3%) 
     Back 408 (21.6%) 155 (29.6%) 
     Shoulder 103 (5.4%) 124 (23.7%) 
     Multisite 973 (51.5%) 42 (8.0%) 
Live alone, n (%) 394 (21.0%) 87 (16.6%) 
Employed, n (%) 747 (41.1%) 234 (46.0%) 
Time off work in last 6 months, n (%) 318 (16.8%) 66 (12.6%) 
Pain @ consultation, mean (SD) n/a 6.3 (2.0) 
Pain intensity, mean (SD)   
     Mean of least, average, & current pain 5.3 (2.4) - 
     Usual pain 6.2 (2.5) 6.2 (2.3) 
Duration: How long since no pain, n (%)   
     < 3 months 403 (21.7%) 136 (26.0%) 
     3-6 months 225 (12.1%) 77 (14.7%) 
     7-12 months 212 (11.4%) 89 (17.0%) 
     1-5 years 521 (27.6%) 128 (24.4%) 
     6+ years 500 (26.5%) 94 (17.9%) 
SF-36 Component Scales , mean (SD)  
(n=116 missing) 
  
     Physical 36.2 (10.1) n/a 
     Mental 43.6 (13.2) n/a 
PROMIS Pain interference, mean (SD)  
(n=46 missing) 
62.1 (8.1) n/a 
Pain self-efficacy, mean (SD), (n=31 missing) 37.2 (16.1) n/a 
Catastrophising, mean (SD), (n=13 missing) 9.7 (8.9) n/a 
Long-term medical conditions, n (%)   
     Diabetes 217 (11.5%) 54 (10.3%) 
     Breathing problems / COPD / Asthma 334 (17.7%) 92 (17.6%) 
     Heart problems or high blood pressure 579 (30.7%) 171 (32.6%) 
     Chronic fatigue, ME, fibromyalgia, WP 84 (4.5%) 43 (8.2%) 
     Anxiety, depression, stress 446 (23.6%) 100 (19.1%) 
     Other 495 (26.2%) 129 (24.6%) 
Health Literacy problems, n (%)   
     Never / rarely 1555 (82.3%) 472 (91.4%) 
     Sometimes / often / always 325 (17.3%) 44 (8.5%) 
EQ-5D-5L, mean (SD) 0.56 (0.27) 0.56 (0.24) 
   




Table 2: Model fit and discrimination of the draft, revised and finals versions of the Keele STarT MSK Tool 
   SF-36 Physical Component  
Summary Score (PCS) 
Pain intensity 









(c-statistic, 95% CI) 
Draft Keele STarT MSK Tool Cohort 2 months 0.337 0.791 (0.766, 0.817) 0.330 0.799 (0.774,0.823) 
  6 months 0.334 0.804 (0.778, 0.830) 0.321 0.785 (0.758, 0.812) 
 
Revised Keele STarT MSK 
tool 
Cohort 2 months 0.405 0.815 (0.792, 0.839) 0.341 0.801 (0.778, 0.825) 
  6 months 0.389 0.817 (0.793, 0.842) 0.331 0.783 (0.757, 0.809) 
 





6 months n/a n/a 0.149 0.685 (0.636, 0.735) 
Final Keele STarT MSK tool Cohort 2 months 0.423 0.818 (0.794, 0.842) 0.429 0.838 (0.816, 0.860) 
  6 months 0.422 0.839 (0.816, 0.863) 0.430 0.822 (0.799, 0.846) 
 
Final Keele STarT MSK tool External 
validation 
 
6 months n/a n/a 0.224 0.725 (0.679, 0.772) 
Additional information on performance of the Final Keele STarT MSK tool in the cohort stratified according to pain site:  
PCS at 2 months – R2=.305 (AUC=.801) [Neck/Shoulder]; R2=.404 (AUC=.803) [Back]; R2=.369 (AUC=.798) [Knee]; R2=.424 (AUC=.814) [Multi-site pain]. 
PCS at 6 months – R2=.289 (AUC=.763) [Neck/Shoulder]; R2=.436 (AUC=.833) [Back]; R2=.351 (AUC=.816) [Knee]; R2=.404 (AUC=.839) [Multi-site pain]. 
Pain at 2 months – R2=.191 (AUC=.749) [Neck/Shoulder]; R2=.382 (AUC=.831) [Back]; R2=.435 (AUC=.831) [Knee]; R2=.424 (AUC=.827) [Multi-site pain]. 






Table 3. Item changes made during refinement of the Keele STarT MSK Tool 
 
Draft Keele STarT MSK Tool item 
 
 
Reason the change was suggested 
 
Final Keele STarT MSK Tool Item* 
 
In the last two weeks, has your 
most painful area been in your 
hand/wrist/elbow or shoulder? 
 
 
Draft tool item not applicable to all pain 
sites. 
 
Do you have any other important health problems? 
Do you feel that pain is terrible 
and it’s never going to get better 
(yes to both)? 
 
Draft tool item was reported to be difficult 
to interpret as it was two questions in one. 
Do you think your pain condition will last a long time? 
In the last 2 weeks, have you had 
pain in more than one part of 
your body? 
Draft tool item was considered to be too 
inclusive and a more specific question 
eliciting information about more severe 
pain may be preferred. 
 
Have you had troublesome joint or muscle pain in more 
than one part of your body? 
n/a Item added to improve model fit and 
discrimination of Final tool. 
 
On average, how intense was your pain [where 0 is “no 
pain” and 10 is “pain as bad as it could be”]? 
n/a Item added to improve model fit and 
discrimination of Final tool. 
 
Have you had your current pain problem for 6 months or 
more? 
n/a Item added to improve model fit and 
discrimination of Final tool. 
 
Do you often feel unsure about how to manage your pain 
condition? 
*The average beta values for the items (original and additional) were (in order of magnitude): 0.31 ‘average pain intensity’; 0.18 ‘pain duration’; 0.18 ‘walk 
short distances’; 0.13 ‘other important health problems’; 0.11 ‘pain condition will last a long time’; 0.08 ‘pain in more than one part of the body’; 0.08 





Table 4: Characteristics and outcomes in the cohort study (refinement and validation) population, overall and within subgroups defined by 
the draft and final Keele STarT MSK tools 
 
   --------------------Draft Keele STarT MSK Tool--------
------------ 
--------------------Final Keele STarT MSK Tool--------
------------ 
  All High risk Medium risk Low risk High risk Medium risk Low risk 
         
SF-36 PCS, mean (SD) Baseline 36.4 (10.1) 29.7 (7.6) 34.0 (8.5) 44.3 (8.2) 28.4 (7.3) 36.8 (8.1) 45.8 (8.0) 
 2 months 38.1 (11.2) 31.3 (9.4) 36.3 (10.2) 45.5 (9.0) 29.7 (8.7) 38.7 (9.5) 47.1 (8.6) 
 6 months 38.6 (11.4) 32.0 (10.1) 36.0 (10.6) 46.1 (8.7) 30.2 (8.8) 39.0 (10.0) 48.0 (8.2) 
         
 ‘Poor’†, n (%) Baseline 647 (40.0%) 379 (71.0%) 214 (44.7%) 54 (9.0%) 399 (73.8%) 227 (33.7%) 27 (6.6%) 
 2 months 560 (47.7%) 273 (75.0%) 204 (56.8%) 83 (18.4%) 295 (80.2%) 233 (46.6%) 42 (13.4%) 
 6 months 581 (53.4%) 256 (80.3%) 227 (66.4%) 98 (22.9%) 287 (87.5%) 257 (53.7%) 43 (15.1%) 
         
Pain intensity, mean (SD) Baseline 5.3 (2.4) 7.0 (1.8) 5.6 (1.7) 3.4 (1.9) 7.2 (1.6) 5.3 (1.7) 2.8 (1.6) 
 2 months 4.4 (2.7) 6.2 (2.4) 4.5 (2.4) 2.7 (2.1) 6.4 (2.2) 4.2 (2.3) 2.2 (1.9) 
 6 months 4.1 (2.8) 5.8 (2.6) 4.4 (2.5) 2.4 (2.1) 6.2 (2.3) 4.0 (2.4) 1.9 (1.9) 
         
 ‘Poor’††, n (%) Baseline 1009 (59.7%) 507 (88.5%) 344 (68.4%) 158 (25.7%) 525 (92.6%) 447 (63.2%) 51 (12.1%) 
 2 months 582 (45.6%) 311 (76.4%) 184 (47.7%) 87 (18.0%) 333 (80.4%) 229 (42.6%) 34 (10.3%) 
 6 months 482 (42.3%) 238 (69.8%) 170 (47.9%) 74 (16.7%) 263 (75.1%) 200 (40.7%) 33 (11.1%) 
         
Promis pain interference  Baseline 62.1 (8.1) 69.0 (5.2) 62.9 (5.2) 54.8 (6.5) 68.8 (4.9) 61.9 (5.6) 53.6 (6.6) 
scale, mean (SD) 2 months 60.1 (8.4) 66.1 (6.3) 60.4 (7.1) 54.2 (7.0) 66.5 (5.8) 59.7 (6.5) 52.9 (7.1) 
 6 months 59.1 (9.0) 65.1 (7.4) 60.3 (7.6) 52.5 (7.3) 65.9 (6.7) 58.4 (7.3) 51.3 (7.4) 
         
EQ5D-L, mean (SD) Baseline .56 (.27) .35 (.28) .58 (.20) .75 (.13) .33 (.26) .62 (.18) .78 (.11) 
 2 months .61 (.26) .43 (.28) .61 (.20) .76 (.15) .40 (.27) .66 (.18) .79 (.13) 
 6 months .62 (.26) .44 (.30) .61 (.22) .78 (.14) .42 (.28) .66 (.19) .81 (.15) 
         
Pain Self Efficacy  Baseline 37.2 (16.1) 24.3 (13.9) 37.0 (12.7) 50.0 (9.7) 24.3 (13.6) 39.3 (12.7) 51.6 (8.8) 
Questionnaire , mean 
(SD) 
6 months 39.9 (16.1) 28.4 (16.0) 38.2 (14.0) 50.6 (10.2) 27.0 (14.5) 42.1 (13.2) 52.3 (10.0) 




   --------------------Draft Keele STarT MSK Tool--------
------------ 
--------------------Final Keele STarT MSK Tool--------
------------ 
  All High risk Medium risk Low risk High risk Medium risk Low risk 
SF-36 Mental Component  Baseline 43.6 (13.2) 34.8 (12.3) 44.6 (11.7) 51.4 (10.2) 35.1 (12.3) 45.4 (11.7) 52.4 (9.1) 
Score, mean (SD) 2 months 47.6 (12.3) 39.7 (13.3) 48.5 (11.1) 53.4 (8.4) 39.5 (12.9) 49.2 (10.8) 54.6 (7.0) 
 6 months 47.7 (11.9) 40.4 (12.9) 47.5 (11.5) 53.6 (7.9) 40.2 (13.0) 49.2 (10.4) 54.1 (7.5) 
         
Pain Catastrophising, 
mean (SD) 
Baseline 9.7 (8.9) 16.4 (9.2) 9.1 (7.2) 4.0 (5.0) 16.3 (9.2) 8.3 (6.8) 3.4 (4.7) 
 6 months 7.8 (8.4) 13.7 (9.5) 8.0 (7.6) 3.0 (4.4) 13.8 (9.3) 6.9 (7.1) 2.4 (4.0) 
         
Sleep problems, n (%) Baseline 1193 (63.1%) 461 (80.7%) 344 (68.8%) 269 (43.6%) 464 (82.1%) 449 (63.7%) 161 (38.4%) 
 2 months 793 (56.7%) 300 (74.6%) 226 (59.8%) 185 (38.2%) 315 (77.6%) 301 (56.8%) 103 (31.1%) 
 6 months 675 (54.3%) 243 (71.7%) 219 (62.2%) 144 (32.7%) 266 (76.4%) 261 (53.5%) 82 (28.0%) 
         
Vigorous physical activity, 
n (%) 
Baseline 710 (38.0%) 116 (20.4%) 186 (37.4%) 345 (56.0%) 106 (18.9%) 296 (42.0%) 252 (59.9%) 
         
Global change 2 months 249 (17.8%) 29 (7.4%) 56 (14.7%) 145 (30.1%) 28 (6.9%) 73 (13.7%) 122 (37.2%) 
“Much improved”, n (%) 6 months 353 (24.3%) 56 (13.3%) 69 (17.3%) 202 (41.0%) 38 (9.0%) 118 (21.0%) 167 (50.1%) 
High versus Medium versus Low risk statistical testing: Between subgroup differences for all summary measures across each time-point (baseline, 2 and 6 
months) for both Tool versions were statistically significant (p<0.001) through one-way ANOVA tests with linear contrast and non-parametric Jonckheere's 
trend (J-T) tests (for numerical outcomes) and by chi-square test-for-trend (for categorical outcomes).  
† ‘Poor’ rating according to pre-assigned cut-points for the PCS of: <33.02 (baseline); <37.17 (2 months); <39.61 (6 months); †† ‘Poor’ rating for Pain across 





Table 5: Construct Validity for Final Keele STarT MSK tool versus (A) ÖMSPQ and (B) STarT Back 
classifications 
A. ÖMSPQ 
 Lower risk# Higher risk# Total 
(i) STarT MSK Tool    
   Low risk 383 (22.6%) 39 (2.3%) 422 (24.9%) 
   Medium/High risk 366 (21.6%) 909 (53.6%) 1275 (75.1%) 
   Total 749 (44.1%) 948 (55.9%) 1697* 
    
Kappa (95% CI) 0.49 (0.45, 0.54) 
[P<0.001] 
Agreement: 
Observed = 76.1% 
Expected = 53.0% 
 
    
(ii) STarT MSK Tool    
   Low/Medium risk 710 (41.8%) 420 (24.7%) 1130 (66.6%) 
   High risk 39 (2.3%) 528 (31.1%) 567 (33.4%) 
   Total 749 (44.1) 948 (55.9%) 1697* 
    
Kappa (95% CI) 0.48 (0.44, 0.52) 
[P<0.001] 
Agreement: 
Observed = 73.0% 
Expected = 48.1% 
* 193 missing STarT 
MSK tool or ÖMSPQ 
scores 
 
B. STarT Back tool 
 Low risk Medium risk High risk Total 
STarT MSK Tool     
   Low risk 105 (18.0%) 15 (2.6%) 2 (0.3%) 122 (20.9%) 
   Medium risk 77 (13.2%) 116 (19.9%) 44 (7.5%) 237 (40.6%) 
   High risk 6 (1.0%) 88 (15.1%) 131 (22.4%) 225 (38.5%) 
   Total 188 (32.2%) 219 (37.5%) 177 (30.3%) 584** 
     
Kappaw (95% CI)^ 0.52 (0.45, 0.58) 
[P<0.001] 
Agreement: 
Observed = 79.5% 
Expected = 57.4% 
 ** 151 missing 
STarT MSK tool or 




0.64 (0.56, 0.70) 
[P<0.001] 
Agreement: 
Observed = 89.0% 
Expected = 69.4% 
  
Percentages within the table are % of the grand total. 
# Categorisation based on a cut-off of <50 (lower risk) and ≥50 (higher risk). 
* Total study population ** Sub-population of participants with back pain (n, 735); back pain only (n, 408) and back 
pain as part of multisite pain (n, 327)). 
^ Weighted-Kappa (linear weights) ^^ Weighted-Kappa (quadratic weights)  
For the numerical scales the overall Pearson correlation coefficient between STarTMSK and OMSPQ was r=0.80; 
correlations by pain area were r=0.76 [Neck], r=0.80 [Back], r=0.71 [Shoulder], r=0.80 [Knee] and r=0.77 [Multisite]. 
Pearson’s correlation between STarT MSK and STarT Back for the back pain subpopulation was r=0.80. 
 
